2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment

ProKidney (NASDAQ: PROK ) is a biotech that works on autologous cellular therapy for organs. In easier terms, PROK tries to preserve organs with its technology, and currently, its leading candidate is Rilparencel (React) for chronic kidney disease [CKD]. In particular, Rilparencel uses patients’ kidney cells to stabilize or slow downMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree ...